AMATOXIN ANTIBODY-DRUG CONJUGATES AND USES THEREOF
Application
US20260078148A1
Kind: A1
Mar 19, 2026
Assignee
Heidelberg Pharma Research GmbH
Inventors
Charlotte Fenton McDonagh, Rajiv Panwar, Torsten Hechler, Michael Kulke, Ganapathy N. Sarma, Andreas Pahl, Christoph Mueller, Werner Simon, Christian Lutz, Francesca Gallo
Abstract
Amatoxins, as well as antibody-drug conjugates (ADCs) and compositions have amatoxin and can be used for cancer therapy, to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure. Methods and compositions treat various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases and prevent graft-versus-host disease (GVHD).
CPC Classifications
C07K 7/64
A61K 45/06
A61K 47/6831
A61K 47/6867
A61P 35/00
C07K 16/2803
C07K 2317/565
C07K 2319/55
Filing Date
2025-11-25
Application No.
19400588